Company news
Aptose Biosciences Inc news in 2026
Aptose Biosciences Inc's news releases, calls and decks from 2026, newest first.
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
June 30, 2026
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
June 15, 2026
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
May 29, 2026
Aptose Reports First Quarter 2026 Results
May 13, 2026
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
April 30, 2026
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
March 31, 2026
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
March 23, 2026
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical
March 19, 2026
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
February 24, 2026